Glucagon-Like Peptide-1 Receptor Agonists and Their Potential Role in Obstructive Sleep Apnea

Tirzepatide is the first medication approved for moderate to severe obstructive sleep apnea in adults with obesity.

• Obstructive sleep apnea affects nearly 1 billion adults globally.
• This condition is independently linked to cardiovascular disease, stroke, and increased mortality.
• Adherence rates to continuous positive airway pressure (CPAP) treatment range from 30% to 60%.
• Obesity is present in 60% to 70% of patients with obstructive sleep apnea.
• The approval of tirzepatide may represent a significant shift toward pharmacological treatment options for this condition.

Simplified